Fujii Y
The benefits and risks of different therapies in preventing postoperative nausea and vomiting in patients undergoing thyroid surgery. [Journal Article]
Curr Drug Saf 2008 Jan; 3(1):27-34.
Postoperative nausea and vomiting (PONV) are distressing and frequent adverse events of anesthesia and surgery, with a relatively high incidence following thyroidectomy. These symptoms predispose to aspiration of gastric contents, increased intraocular pressure, psychological distress, and delayed recovery and discharge times. Numerous antiemetics have been studied for the prevention and treatment of PONV following thyroidectomy. These drugs include butyrophenones (e.g., droperidol), benzamides (e.g., metoclopramide), antihistamines (e.g., dimenhydrinate), corticosteroids (e.g., dexamethasone), propofol, oxygen, and serotonon receptor antagonists (e.g., ondansetron). Most of published trials indicate improved prophylaxis against PONV by avoiding risk factors and/or by using effective antiemetic therapy in patients scheduled for thyroid surgery. Traditional antiemetics (droperidol, metoclopramide, and alizapride), non-traditional antiemetics (propofol and dexamethasone), and serotonin receptor antagonists (ondansetron, granisetron, tropisetron, dolasetron, and ramosetron) have been studied for the prevention of PONV. Serotonin receptor antagonists are more effective than traditional antiemetics. Combination antiemetic therapy with granisetron plus droperidol or granisetron plus dexamethasone is highly effective in preventing PONV. The benefits and risks of different therapies are needed to prevent PONV following thyroid surgery.
More from this journal |
